<div class="infobox infobox-company">
<div class="infobox-header">Lysosomal Therapies Inc</div>
<div class="infobox-row"><strong>Headquarters:</strong> San Diego, CA, USA</div>
<div class="infobox-row"><strong>Founded:</strong> 2021</div>
<div class="infobox-row"><strong>Focus:</strong> Lysosomal enzyme activation</div>
<div class="infobox-row"><strong>Status:</strong> Private</div>
<div class="infobox-row"><strong>Funding:</strong> Series A ($28M, 2024)</div>
<div class="infobox-row"><strong>CEO:</strong> Dr. Andrew Freeman</div>
</div>
<div class="infobox infobox-company">
<div class="infobox-header">Lysosomal Therapies Inc</div>
<div class="infobox-row"><strong>Headquarters:</strong> San Diego, CA, USA</div>
<div class="infobox-row"><strong>Founded:</strong> 2021</div>
<div class="infobox-row"><strong>Focus:</strong> Lysosomal enzyme activation</div>
<div class="infobox-row"><strong>Status:</strong> Private</div>
<div class="infobox-row"><strong>Funding:</strong> Series A ($28M, 2024)</div>
<div class="infobox-row"><strong>CEO:</strong> Dr. Andrew Freeman</div>
</div>
Lysosomal Therapies Inc is a US-based biotechnology company developing small molecule therapeutics that enhance lysosomal protease activity for the treatment of neurodegenerative diseases. The company's lead program, LYS-01, is a cathepsin D activator designed to enhance lysosomal proteolytic capacity in Parkinson's disease. Founded in 2021 by leading lysosomal biology researchers from The Scripps Research Institute and the University of Michigan, the company focuses on directly enhancing the activity of lysosomal cathepsins rather than increasing lysosomal numbers through transcription factor activation.
The company raised $28 million in Series A financing in 2024, led by OrbiMed Advisors with participation from founding investor MPM Capital. This funding enabled the advancement of LYS-01 into lead optimization and IND-enabling studies.
| Program | Indication | Stage | Mechanism | Expected Milestone |
|---------|------------|-------|------------|-------------------|
| LYS-01 | Parkinson's Disease | Preclinical | Cathepsin D activator | IND submission 2027 |
| LYS-02 | Alzheimer's Disease | Discovery | Cathepsin B/D activator | Lead selection 2026 |
| LYS-03 | Lysosomal Storage Disorders | Discovery | Multi-cathepsin activator | Lead selection 2027 |
| LYS-04 | Dementia with Lewy Bodies | Discovery | Cathepsin D activator | Target identification |
Lysosomal cathepsins are critical for intracellular protein clearance and play a key role in degrading aggregated proteins that accumulate in neurodegenerative diseases[@cuervo2004] [1][2]. The major lysosomal proteases involved in neurodegeneration include:
Cathepsin D, the primary aspartyl protease in lysosomes, is particularly important for alpha-synuclein degradation. Studies have demonstrated that cathepsin D can cleave alpha-synuclein at multiple sites, generating fragments that are less prone to aggregation while also promoting the clearance of existing aggregates[@dehay2012] [3][4]. The enzyme shows reduced activity in PD brain tissue, and genetic variants in the CTSD gene are associated with increased PD risk, establishing a direct link between cathepsin D function and Parkinson's disease pathogenesis.
Cathepsin B, a cysteine protease, also demonstrates alpha-synuclein degrading activity with different cleavage specificity than cathepsin D [5]. The combination of cathepsin B and D activity provides more comprehensive alpha-synuclein clearance than either enzyme alone, suggesting that multi-cathepsin activation could provide superior therapeutic benefit.
Cathepsin L preferentially degrades tau protein and has been shown to reduce tau pathology in cellular and animal models [6]. The selective activation of cathepsin L may therefore provide particular benefit in Alzheimer's disease where tau pathology is a major driver of neurodegeneration.
In Parkinson's disease, lysosomal protease activity is significantly reduced[@wallings2019] [7]:
Lysosomal Therapies takes a direct approach to restoring lysosomal function, distinct from strategies that increase lysosomal numbers (such as TFEB activation):
This direct activation approach offers potential advantages over transcription factor-based strategies:
LYS-01 promotes lysosomal proteolysis through multiple complementary mechanisms:
Preclinical studies in cellular models have demonstrated that LYS-01 treatment results in:
Lysosomal Therapies employs multiple complementary approaches to cathepsin activator discovery:
The company prioritizes several key attributes in its drug development program:
Lysosomal Therapies is developing biomarkers to support clinical development:
The lysosomal enhancement field encompasses multiple therapeutic approaches:
| Company | Approach | Stage | Differentiation |
|---------|----------|-------|-----------------|
| Lysosomal Therapies Inc | Cathepsin activator | Preclinical | Direct enzyme activation |
| Gain Therapeutics | GCase chaperone | Phase 1b | Substrate reduction |
| Lysoway Therapeutics | TRPML1 agonist | Preclinical | Lysosomal calcium modulation |
| Appvian | TFEB activator | Preclinical | Lysosomal biogenesis |
| AtlasX Bio | TFEB activator | Phase I planned | Brain-penetrant, oral |
| Car Ther Bio | TFEB AAV | Preclinical | Gene therapy |
Lysosomal Therapies maintains several unique competitive advantages:
Lysosomal Therapies is pursuing strategic partnerships to accelerate development:
The addressable market for lysosomal-targeted therapies in neurodegeneration:
| Indication | Market Size (2035) | Annual Growth |
|------------|-------------------|---------------|
| Parkinson's Disease | $12B | 8.5% |
| Alzheimer's Disease | $28B | 6.2% |
| Dementia with Lewy Bodies | $3B | 9.1% |
| Lysosomal Storage Disorders | $8B | 7.1% |
LYS-01 has demonstrated promising efficacy in multiple preclinical models:
The clinical development plan for LYS-01 includes:
Lysosomal Therapies maintains a strong intellectual property portfolio:
| Round | Amount | Year | Lead Investors |
|-------|--------|------|----------------|
| Seed | $5M | 2021 | MPM Capital |
| Series A | $28M | 2024 | OrbiMed, MPM Capital |
Series A funding is allocated:
Lysosomal Therapies aims to become the leading company in direct lysosomal protease enhancement for neurodegenerative diseases. The company's approach of directly activating cathepsins represents a paradigm shift from indirect approaches like TFEB activation, offering the potential for rapid therapeutic benefit either as monotherapy or in combination with other lysosomal-targeted approaches.
The company is also exploring applications in Alzheimer's disease (through cathepsin B/L activation), dementia with Lewy bodies, and lysosomal storage disorders where similar lysosomal dysfunction contributes to disease pathology.